The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy.
Bosutinib
Dasatinib
Healthcare cost
Imatinib
Nilotinib
Ponatinib
Real-life
Tyrosine kinase inhibitors
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
27
10
2022
accepted:
01
12
2022
pubmed:
24
12
2022
medline:
9
3
2023
entrez:
23
12
2022
Statut:
ppublish
Résumé
Chronic myeloid leukemia (CML) is a hematopoietic myeloproliferative disorder that accounts for 20% of all leukemias of adults. The introduction of tyrosine kinase inhibitors (TKIs) (imatinib, bosutinib, dasatinib, nilotinib, ponatinib) has yielded significant benefits for patients with CML in terms of survival and quality of life. This real-world analysis evaluated the economic burden for managing patients with CML in 2nd or ≥ 3rd TKI lines in Italian settings of clinical practice. A retrospective observational analysis was performed exploiting the administrative databases of a sample of entities covering around 15 million inhabitants. From 2015 to 2018, the study included adult patients with at least one prescription for TKIs, (and for some TKI with at least one hospitalization discharge diagnosis for CML, or at least one prescription for BCR-ABL examination). The index date was the first TKI prescription. Healthcare resource consumption and costs for patients with CML in 2nd and ≥ 3rd line treatment with TKIs were analyzed for drug prescriptions, hospitalizations, specialist visits, and diagnostic services. In total 635 patients were included, 491 in 2nd line and 144 in 3rd line with TKIs. Dasatinib was the most frequently prescribed drug in 2nd line (28.9%) and imatinib in later lines (26.4%). With progressing lines of treatment, healthcare consumption showed a trend towards increased non-TKI prescriptions per patient (8 for 2nd line and 9.7 for ≥ 3rd line). The management of patients with CML in later lines resulted in increased overall healthcare burden, with hospitalizations accounting for about half of total expenditure, whatever the treatment line and type of TKI. This analysis in Italian real-life clinical practice reported economic expenditure for patients with CML in 2nd or ≥ 3rd lines with TKIs, mostly burdened by hospitalizations. Such clinical complexity suggests that further efforts are needed to improve the therapeutic management of later lines of CML.
Identifiants
pubmed: 36562943
doi: 10.1007/s12325-022-02398-6
pii: 10.1007/s12325-022-02398-6
pmc: PMC9989002
doi:
Substances chimiques
Antineoplastic Agents
0
Dasatinib
RBZ1571X5H
Imatinib Mesylate
8A1O1M485B
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
961-974Informations de copyright
© 2022. The Author(s).
Références
Chopade P, Akard LP. Improving outcomes in chronic myeloid leukemia over time in the era of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2018;18:710–23.
doi: 10.1016/j.clml.2018.06.029
pubmed: 30093283
De Santis S, Monaldi C, Mancini M, Bruno S, Cavo M, Soverini S. Overcoming resistance to kinase inhibitors: the paradigm of chronic myeloid leukemia. Onco Targets Ther. 2022;15:103–16.
doi: 10.2147/OTT.S289306
pubmed: 35115784
pmcid: 8800859
Lin Q, Mao L, Shao L, et al. Global, regional, and national burden of chronic myeloid leukemia, 1990–2017: a systematic analysis for the global burden of disease study 2017. Front Oncol. 2020;10:580759.
doi: 10.3389/fonc.2020.580759
pubmed: 33384954
pmcid: 7770240
Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–193.
doi: 10.1016/S2352-3026(15)00048-4
pubmed: 26688093
pmcid: 4884053
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.
doi: 10.1038/s41375-020-0776-2
pubmed: 32127639
pmcid: 7214240
Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41–51.
doi: 10.1093/annonc/mdx219
pubmed: 28881915
Baccarani M, Abruzzese E, Accurso V, et al. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Adv. 2019;3:4280–90.
doi: 10.1182/bloodadvances.2019000865
pubmed: 31869412
pmcid: 6929396
McGarry LJ, Chen YJ, Divino V, et al. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Curr Med Res Opin. 2016;32:289–99.
doi: 10.1185/03007995.2015.1120189
pubmed: 26566171
Hochhaus A, Breccia M, Saglio G, et al. Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34:1495–502.
doi: 10.1038/s41375-020-0842-9
pubmed: 32366938
pmcid: 7266739
Patel AB, O’Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am. 2017;31:589–612.
doi: 10.1016/j.hoc.2017.04.007
pubmed: 28673390
pmcid: 5505321
Zhang S, Maegawa R, Nandal S, Patwardhan P. Targeted literature review of patient reported outcomes (PROs) in chronic myeloid leukemia (CML) patients receiving second and later lines of treatment. Blood. 2020;136:26–7.
doi: 10.1182/blood-2020-140402
Negi H, Agrawal R, Vieira J, Ryan J, Thakur D, Viana R. PCN231 humanistic and economic burden in patients with chronic myeloid leukemia â—a review of the literature. Value Health. 2021;24:S63.
doi: 10.1016/j.jval.2021.04.321
Breccia M, Chiodi F, Nardozza AP, et al. Real-world analysis of the therapeutic management and disease burden in chronic myeloid leukemia patients with later lines in Italy. JCM. 2022;11:3597.
doi: 10.3390/jcm11133597
pubmed: 35806885
pmcid: 9267241
Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM-L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7.
doi: 10.1200/JCO.2015.66.2866
pubmed: 27325849
Lucioni C, Iannazzo S, Mazzi S, Saporiti G, Chiroli S. Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy: Valutazione di costo-efficacia di ponatinib nella terapia della leucemia mieloide cronica in Italia. Global Reg Health Technol Assess. 2015;2:1–16.
Bonifacio M, Maheshwari V, Tran D, Agostoni G, Filioussi K, Viana R. Economic model to evaluate the cost-effectiveness of second-line nilotinib versus dasatinib for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML-CP) in Italy. Pharmacoecon Open. 2021;6:95–104.
doi: 10.1007/s41669-021-00286-3
pubmed: 34297312
pmcid: 8807738
Guérin A, Guo A, Williams D, et al. Treatment patterns of chronic myelogenous leukemia patients with suboptimal responses to imatinib. J Clin Oncol. 2009;27:7090–7090.
doi: 10.1200/jco.2009.27.15_suppl.7090
Campiotti L, Suter MB, Guasti L, et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR–ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer. 2017;77:48–56.
doi: 10.1016/j.ejca.2017.02.028
pubmed: 28365527
Jabbour EJ, Lin J, Siegartel LR, Lingohr-Smith M, Menges B, Makenbaeva D. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase. J Med Econ. 2017;20:1007–12.
doi: 10.1080/13696998.2017.1345750
pubmed: 28681664
Erçalışkan A, Seyhan Erdoğan D, Eşkazan AE. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Adv. 2021;5:3344–53.
doi: 10.1182/bloodadvances.2021004194
pubmed: 34477815
pmcid: 8525239